From: precisiononcologynews.com The University of Southern California’s Norris Comprehensive Cancer Center on Monday said it has opened a Phase II trial of Ambrx’s antibody-drug conjugate ARX788 for advanced HER2-positive breast cancer patients. The trial, which is sponsored by La Jolla, California-based Ambrx, will involve roughly 200 HER2-positive metastatic breast cancer patients who have previously received trastuzumab emtansine (Genentech’s Kadcyla; T-DM1), …
Newfound protein may prevent viral infection and herpes-induced cancer
Provided by: University of Southern California From: phys.org Keck School of Medicine of USC researchers have identified a human protein that could prevent cancer by restricting a type of herpes virus from replicating. The scientists examined the human herpes virus 8, otherwise known as Kaposi’s sarcoma-associated herpesvirus. Kaposi sarcoma is a cancer that causes lesions in soft tissue, including skin, …